Alcobra Ltd (ADHD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Alcobra Ltd (Alcobra) is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products and novel treatments for CNS. The company offers non-stimulant products that are used in treatment of central nervous system disorders and cognitive dysfunctions. It provides development and commercialization of its investigational new novel Phase III drug candidate, metadoxine extended release. Alcbras MDX acts as a monoamine-independent modulator of GABA transmission. The company conducts clinical studies and separate Phase IIb trials of MDX. It also provides phase II studies and a phase III study of MDX in adults with ADHD. Alcobra is headquartered in Tel Aviv, Israel.

Alcobra Ltd (ADHD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

3
List of Tables 4
List of Figures 4
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alcobra Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Alcobra Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra 10
Merger 11
Alcobra and Arcturus Therapeutics to Merge 11
Equity Offering 13
Alcobra Raises USD41.5 Million in Public Offering of Shares 13
Alcobra Raises USD29.9 Million in Public Offering of Shares 15
Alcobra Completes Public Offering Of Shares For US$38 Million 17
Alcobra Completes IPO For US$25 Million 19
Acquisition 21
Regenera Pharma May Acquire 66.6% Stake in Alcobra Pharma 21
Alcobra Ltd - Key Competitors 22
Alcobra Ltd - Key Employees 23
Alcobra Ltd - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Strategy And Business Planning 25
Jun 23, 2017: Alcobra Updates On Its Review Of Strategic Alternatives 25
Financial Announcements 26
Nov 09, 2017: Alcobra Announces Third Quarter 2017 Financial Results and Provides Corporate Update 26
Aug 11, 2017: Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update 27
May 30, 2017: Alcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update 28
Feb 15, 2017: Alcobra Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Corporate Update 29
Nov 15, 2016: Alcobra Announces Third Quarter 2016 Financial Results and Provides Corporate Update 30
Aug 30, 2016: Alcobra Announces Second Quarter 2016 Financial Results and Provides Corporate Update 31
May 16, 2016: Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update 32
Feb 17, 2016: Alcobra Announces Fourth Quarter And Fiscal 2015 Financial Results And Provides Corporate Update 33
Corporate Communications 34
May 15, 2017: Alcobra Announces Leadership Update 34
Product Approvals 35
Feb 06, 2017: Alcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD 35
Jul 19, 2016: Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List Of Tables

List of Tables
Alcobra Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alcobra Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alcobra Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Alcobra Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra 10
Alcobra and Arcturus Therapeutics to Merge 11
Alcobra Raises USD41.5 Million in Public Offering of Shares 13
Alcobra Raises USD29.9 Million in Public Offering of Shares 15
Alcobra Completes Public Offering Of Shares For US$38 Million 17
Alcobra Completes IPO For US$25 Million 19
Regenera Pharma May Acquire 66.6% Stake in Alcobra Pharma 21
Alcobra Ltd, Key Competitors 22
Alcobra Ltd, Key Employees 23
Alcobra Ltd, Subsidiaries 24

Alcobra Ltd (ADHD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Alcobra Ltd (Alcobra) is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products and novel treatments for CNS. The company offers non-stimulant products that are used in treatment of

USD 250 View Report

Alcobra Ltd (ADHD) - Financial and Strategic SWOT Analysis Review

Alcobra Ltd (Alcobra) is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products and novel treatments for CNS. The company offers non-stimulant products that are used in treatment of

USD 300 View Report

Alcobra Ltd (ADHD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Alcobra Ltd (Alcobra) is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products and novel treatments for CNS. The company offers non-stimulant products that are used in treatment of

USD 250 View Report

Alcobra Ltd (ADHD) - Financial and Strategic SWOT Analysis Review

Alcobra Ltd (Alcobra) is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products and novel treatments for CNS. The company offers non-stimulant products that are used in treatment of

USD 300 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available